HSPA4 and gastric cancer: In addition, we report that, although HSPA4 upregulation is correlated with poor prognosis in patients with GC, HSPA4 upregulation could be a valuable biomarker for predicting better response to PD1 checkpoint blockade therapy for GC patients.